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The potential of genetically modified organisms (GMOs) to increase allergenicity or predispositions to allergies has attracted 
much attention. An approach that will properly and holistically evaluate the allergenicity of GMOs is yet to be found. Here, 85 
transgenes that have been reported in both international and domestic studies during recent years are summarized case by case; 49 
of the transformed genes were from plant sources and 36 were from animal sources. EVALLER™, a web server for the in silico 
assessment of potential protein allergenicity, was used to evaluate the potential of the transgenic proteins as allergens. The bio-
medical journals listed in Highwire (http://highwire.stanford.edu/) were searched and reviewed to decipher whether any of the 
transformed genes were linked to allergenicity or human health. The EVALLER analysis identified 5 allergenic genes, whilst our 
literature review found 11 genes that were either related to allergic cases or to clinical adverse events; all 16 of these genes have 
been used in GMOs. The analysis pathway that we have developed can help guide the selection of genes to be used in genetic 
modification. The pathway also provides a paradigm for allergenicity analysis of transgene candidates. 
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A genetically modified organism (GMO) is a novel organ-
ism whose genetic material has been altered using trans-
genic biotechnology. Examples of GMO techniques include, 
but are not limited to, transferring of foreign genes from 
viruses, bacteria or non-food species, and transferring fa-
vorable or resistance genes from one food species to another 
food species or to one with less favorable target properties. 
GMOs have been shown to have incomparable advantages 
over traditionally bred products. GMOs break through the 
biological species concept, and consequently, more and more 
are being developed and put to widespread use. However, 
alongside the significant socioeconomic benefits that are 
generated, the biomedical safety of GMOs has increasingly 
come under public scrutiny. Safety evaluations prior to a 
GMO becoming commercial availability can be important 
in eliminating or minimizing the negative impacts and dis-
trust of GMOs, and the risks of untoward food reactions and 
gastrointestinal disease could be reduced. The potential for 
increased allergenicity or predisposition to allergies caused 
by GMOs harboring novel proteins (as in the transgenic 
plants and animals that could become the mainstay of food 
sources for human), has attracted much attention from gov-
ernments and communities worldwide. Therefore, an ap-
proach for the proper and overall evaluation of the aller-
genicity of each of the exotic gene introduced into GMOs 
remains an important topic to be addressed. 
The aim of the present study was to summarize the aller-
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genicity of target genes that have been used in GMOs both 
internationally and domestically in recent years. We included 
a total of 85 transformed genes, 49 from plant sources and 36 
from animal sources, in the study. These genes were re-
trieved from a bioinformatics databank, their protein coding 
regions were identified and the deduced amino acid se-
quences were evaluated for potential allergenicity. Litera-
ture on these 85 transformed genes was searched and re-
viewed to decipher whether or not they had been linked to 
allergenicity or human health. The information obtained 
could be used to guide the selection of genes to be used in 
genetic modification, as well to provide a paradigm for the 
allergenicity analysis of transgenes. 
1  Materials and methods 
1.1  Data source of the transgenes 
International and domestic studies on GMOs published in 
recent years for which the full-text articles were available in 
the common literature databases (Highwire, PubMed and 
CNKI) were identified using the search terms “genetically 
modified organism”, “transgenic organism” and a Chinese 
key word “transgenic gene”. When there was redundant 
data on any individual gene (a gene with identical primer 
sequences and gene name) because, for example, it had 
been transformed to a variety of species, only one of the 
related articles was selected in our study and the remaining 
articles were excluded. 
1.2  Acquisition of information on the transgenes 
All bioinformatic data including primer sequences and gene 
names were extracted from the full-texts and searched against 
the nucleotide sequence database available at the National 
Center for Biotechnology Information (NCBI) using the 
Basic Local Alignment Search Tool (BLAST) to acquire the 
nucleotide sequences of the genes and their annotated pro-
tein coding regions (CDSs). The CDS sequences were used 
to retrieve in-depth information from the Universal Protein 
Resource (UniProt) database; the Uniprot ID number and 
the corresponding amino acid sequence in FASTA format 
was extracted for each transgene. 
1.3  E-testing of protein allergenicity 
“E-testing of protein allergenicity” was performed using the 
software EVALLERTM (version 2.0) [1], a web server for 
the bioinformatics assessment of protein allergenicity. This 
tool is available on the “Food Safety” page (http://www.slv. 
se/en-gb/Group1/Food-Safety/e-Testing-of-protein-allergeni
city/) of the National Food Agency, Sweden. Genes that were 
labeled as allergenic were further investigated in a number 
of common allergen databases (Table 1) to determine wheth-
er or not the allergens have been well-documented. 
1.4  Retrieval of medical reports with negative com-
ments on transgenes 
Medical articles related to the transgenes were searched for 
in the biomedical journals listed in Highwire (http://www. 
highwire.org) using the gene names or their abbreviations, 
obtained as described in Section 1.2 above, as keywords and 
setting “include PubMed” as the filter mode. The full-texts 
of papers with abstracts containing negative comments on 
any of the transgenes were downloaded and saved for fur-
ther confirmation. 
2  Results 
2.1  Collection of the transgenes 
A search of transgene data (as of July 1, 2010) yielded 85 
hits, 49 from plant sources and 36 from animal sources. The 
hosts for the transgenes included 13 plant species: rice, 
soybean, wheat, corn, rape (including Brassica napus), potato,  
Table 1  Databases used in this study 
Database Website References 
EVALLER http://www.slv.se/en-gb/Group1/Food-Safety/e-Testing-of-protein-allergenicity/ [1] 
GenPept http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein [2] 
UniProt/SwissProt http://www.uniprot.org [3,4] 
IUIS allergens http://www.allergen.org [5] 
Allergen database http://allergen.csl.gov.uk/ [6] 
Allergome http://www.allergome.org/ [7] 
Allermatch http://www.allermatch.org [8] 
SDAP-structural database of allergenic proteins http://fermi.utmb.edu/SDAP/ [9] 
CSL allergen http://www.fera.defra.gov.uk/ [10] 
FARRP  http://allergenonline.com [11] 
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the tetraploid Robinia pseudoacacia, white clover, cotton, 
rye, tomato and tobacco; and 4 animal species: pig, cattle, 
sheep (including domestic sheep and goat) and mouse. The 
characters of the transgenes from plant sources mainly in-
clude the capacity for resistance to adversities (diseases, 
pests, drought and land salinization), aging, low temperature 
and insecticides, or their improvement to species quality, 
photosynthesis, bioavailability of limited elements from the 
soils, and their content of elements deficient in the human 
body. The transgenes from animal sources covered a range 
of benefits such as therapeutic effects for human diseases, 
and improved qualities and accelerated growth of the trans-
genic products. Detailed information on the sources, hosts, 
functions and use of all the transgenes collected is summa-
rized in Table 2 and in Tables S1 and S2. The plant-based 
cell cycle regulatory protein cyclAt gene (ID #1 transgene in 
Table S1) originating from Arabidopsis, for example, could 
be useful for modulation of growth and development in 
plants, and the animal-based HSA gene (ID #8 transgene in 
Table 2) which was transformed from human to sheep, cat-
tle and pig, could play a major role in the treatment of mas-
sive blood loss, burns, shock, edema and hypoalbuminemia, 
and may also be important in the manufacture of protective 
agents or stabilizers for various biological products and bi-
ochemical reagents. 
2.2  E-testing of allergenicity of the transgenes 
The transgene names and the sequences of the corresponding 
primers that were available in the full-texts were obtained.  
Table 2  Summary of the transforming genes identified using our analysis pathway to be involved in allergenicity or adverse eventsa) 
No. Transforming genes Source Host Function and application Allergenicity 
Allergy- or AE- 
related literature 
Reference 
1 Wheat germ agglutinin  
(WGA) 
Wheat Indian mustard Resistance of European corn borer Yes √ [12] 
2 
Wheat HMW leucosin (1Dx5,  
1Dy10) 
Wheat Rye  
Improve processing quality of wheat 
and baking quality Yes √ [13] 
3 Bchi String bean 
Wheat, brassica  
napus, rape 
Resistance of powdery mildew and 
gibberellic disease Yes √ [14] 
4 Phytase* Asp. niger Corn, rice 
Improve utilization ratio of phos-
phorus and absorption of iron zinc No √ [15] 
5 Lysozyme* Human Rice 
Improve quality of milk and its an-
timicrobial activity No √ [16] 
6 Beta-glucuronidase (GUS)* E. coli 
Rice, soybean,  
wheat, corn 




Barley Wheat Resistance of fungus disease No √ [18] 
8 Human serum albumin (HSA) Human 
Domestic 
sheep/cow/pig 
Mainly used for massive blood loss, 
burns, shock, edema, hypopro-
teinemia, etc; meanwhile the stabi-
lizing agent and protective agent of 
various biological products, bio-
chemical reagents 
Yes √ [19] 
9 
Cheese protein (beta casein  
CSN2, kappa casein CSN3) 
Cow Cow Improve cheese content in milk Yes √ [20] 
10 Phytase* E. coli Pig 
Improve digestion rate of phospho-
rus, decrease phosphorus content in 
pig manure, protecting environment 
No √ [21] 
11 Lysozyme (LZ)* Human Sheep 
Improve quality of milk and its an-
timicrobial activity No √ [22] 
12 Insulin* Human Cow Treatment of diabetes No √ [23] 
13 
Tissue-type plasminogen  
activator (tPA)* 
Human/mouse Goat/pig 
Thrombolytic, used for acute myo-
cardial infarction No √ [24] 
14 Alpha-1-antitrypsin (AAT)* Human Domestic sheep Treatment of fibrosing alveolitis No √ [25] 
15 Lactoferrin (LF)* Human 
Domestic 
sheep/cow 
Nourishment and medicine for chil-
dren, the aged and patients with 
immunologic inadequacy; medi-
cine for patients with anemia 
No √ [26] 
16 Hemoglobin* Human Swine Obtain effective constituent of blood  No √ [27] 
17 Antithrombin III (rhATIII)* Human Goat 
Treatment of antithrombin deficiency 
disease; thromboprophylaxis; he-
mostasis 
No √ [28] 
18 
Decay accelerating factor  
(hDAF)* 
Human Pig 
Reduce hypersensitive rejection reac-
tion of xenotransplantation No √ [29] 
a) * indicates the transgene proteins that were not EVALLER-judged as allergenic but related to allergies or adverse events according to the references. 
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For each gene, a consensus motif was generated by concat-
enating the forward primer to the reverse complemented 
sequence of the reverse primer with a string of N’s between 
them. The consensus sequences were used to query the nu-
cleotide sequence database at NCBI using the BLASTn 
program and all the sequences that matched a particular 
consensus motif were downloaded. Sequences with species 
origin and gene name consistent with what was described in 
the full-texts were selected as the target sequences. Using 
this procedure we obtained 85 full-length coding sequences 
of transgenes from which we generated the deduced protein 
sequences using a gene translation tool. The protein se-
quences were saved in FASTA format after confirming with 
NCBI/BLASTp program that the back-translations pro-
duced the original target sequences. 
E-testing of allergenicity was performed using the de-
duced protein sequences of the transgenes. For example, the 
FASTA sequence of the HSA gene (ID #8 transgene in Ta-
ble 2), was pasted into the acceptor window of EVALLER 
2.0 and the results of the allergenicity assessment were gen-
erated (Figures 1 and 2). The red-barred query shown in 
Figure 1 is an indication that the tested protein is an allergen. 
The five filtered length-adjusted allergen peptides (FLAPs) 
that best matched human serum albumin, are given in Fig-
ure 2. The results of the e-testing helped determine the al-
lergenicity of some protein and allowed the error by which a 
misjudgment was made to be quantified. EVALLER also 
indicted that if the HSA gene was not allergenic then it 
would be non-allergenic in 0.0% of the times; this may be 
interpreted as a full confirmation on the allergenicity of 
HSA. Human serum albumin (HSA) has typically been used 
as a non-allergenic negative control or stabilizer in allergen 
assays and in other experiments [30]. The allergen predic-
tion result for HSA was supported by the earlier observation 
that HSA may arouse allergy after being conjugated with 
plicatic acid or other haptens [31]. 
The results of the evaluation for allergenicity of the 
plant-based cell cycle regulatory protein (ID #1 transgene in 
Table S1) are shown in Figures 3 and 4. A difference to be 
noted is the green-barred query which indicated that the 
protein was predicted to be non-allergenic; however, the 5 
best FLAPs shown in Figure 4 have an error possibility of 
only 6.8%. An alternative interpretation is that the risk of 
committing an error could be greater than 5% when the cell 
cycle regulatory protein was considered to have no aller-
genicity. Further validation of these findings in future stud-
ies is warranted. 
2.3  Consideration of a special case 
Cowpea trypsin inhibitor (CPTI, ID #5 transgene in Table 
S1), a gene with insect-resistant capacity that has been 
transformed into a number of crops, is generally believed to 
have no allergenicity. However, the sequence with the sig-
nal peptide intact was determined as definitely allergenic by 
EVALLER. It has been suggested that the CPTI signal pep-
tide in cells of transgenic plants may deliver novel in-
sect-resistant fusion proteins into the endoplasmic reticulum 
(ER) before it is recognized and truncated by some recogni-
tion mechanism [32]. Removal of the signal peptide was 
associated with the EVALLER prediction of the non-aller-      
genicity of CPTI. If CPTI in transgenic products can be 
confirmed to exist only in the form of the mature peptide 
(containing no signal peptides), then this outcome of e- 
testing with EVALLER may eventually shed light upon the 
allergenicity of the products of this transgene. 
2.4  Literature review reveals false negatives predicted 
by EVALLER 
Of the 49 plant-based transgenes only 3, wheat germ agglu-
tinin (ID #1 transgene in Table 2), wheat HMW leucosin 
(ID #2 transgene in Table 2) and Leguminosae chitin syn-
thetase (ID #3 in Table 2) and, of the 36 animal-based 
transgenes only 2, human serum albumin (ID #8 transgene 
in Table 2) and cheese protein (ID #9 transgene in Table 2)  
 
Figure 1  Evaluation of the allergenicity of the human serum albumin gene (ID #8 transgene of animal source in Table 2) using EVALLER. The 
EVALLAR assignment of a red bar at the top of the output page represents a positive outcome (“allergen”); five filtered length-adjusted allergen peptides 
(FLAPs) were returned; the FLAP that best matches the target gene is the darkest. 
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Figure 2  Evaluation of the allergenicity of serum albumin (ID #8 transgene of animal source in Table 2) showing the 5 best-matching FLAPs. 
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Figure 3  Evaluation of the allergenicity of the cell cycle regulatory protein gene (ID #1 transgene of plant source) using EVALLER. The EVALLAR as-
signment of a green bar at the top of the output page represents a negative outcome (“non-allergen”); five filtered length-adjusted allergen peptides (FLAP) 
were returned; the FLAP that best matched the target gene is the darkest. 
were predicted by EVALLER to be allergens; the remaining 
transgenes were predicted to be non-allergenic. However, 
our review of the literature revealed a number of allergies or 
adverse events that were associated with several of the 
transgene proteins that were not EVALLER-judged as al-
lergenic. These proteins are identified with an asterisk (*) in 
Table 2. The use of these 11 transgenes in GMOs should 
therefore be approached with caution. 
For instance, although the antithrombin III protein (ID 
#17 transgene in Table 2) was not predicted to be allergenic, 
in one study, it was recommended that it was not to be used 
in patients with severe disorders [33].  
Thioredoxin, one of the proteins predicted with definite 
allergenicity [34], should be avoided as a candidate for gene 
transformation. However, transformation of its antisense 
gene could presumably be less allergenic and our review of 
the literature indicated that thioredoxin may reduce disul-
fide bonds and thereby lower the allergenicity of certain 
transgenic products [35]. This may be interpreted as the 
high allergenicity of a product being reversed by the anti-
sense gene of thioredoxin. Therefore, the antisense trans-
formation or knockout of thioredoxin needs special consid-
erations when it is used in GMOs. 
3  Discussion 
In recent years, the safety profiles of genetically modified 
organisms (GMOs) have drawn much attention from gov-
ernments, scientists and the public worldwide. Safety eval-
uation has been the only gateway for transgenic products to 
be marketed and put on dining-tables. Among all items 
listed in the safety evaluation, allergenicity of GMOs ap-
pears to be particularly important. A major example is the 
one of Pioneer Hi-Bred International Inc. which, in 1996, 
successfully transferred the 2S albumin gene from Brazil 
nuts (Bertholletia excelsa) into soybeans to improve the 
nutritional quality of the latter. Unfortunately for them, the 
radioallergosorbent assay revealed this gene to be an aller-
gen. Because the soybeans with 2S albumin gene were highly 
likely to cause allergic reactions in humans, they were 
eventually not approved for commercial availability [36] 
becoming instead a great waste of the company’s substantial 
investments in labor, material resources and finance. In 
2001, the US Center of Disease Control and Prevention 
(CDC) filed around hundred cases of immune response al-
legedly associated with the consumption of a transgenic 
corn containing the insecticidal protein CRY9C. The issue 
of allergenicity to CRY9C was left unresolved because the 
link was not supported by the ELISA test carried out by the 
Food and Drug Administration [37]. These examples under-
line the value of using clinical evidences in the assessment 
of allergenicity. 
In the present study, a total of 85 transgenes along with 
their sources, hosts, functions and uses were summarized, 
paying special attention to any reported allergenicity and 
related adverse effects. The algorithm that we developed to 
create the summary warrants standardization in future studies. 
First, medical literature and gene databases were searched 
to acquire bioinformatic data for the 85 transgenes. Evalua-
tion of allergenicity of the deduced protein sequences was 
then performed using EVALLER 2.0. Five of the 85 
transgenes, wheat germ agglutinin, wheat HMW leucosin, 
string bean chitinase, human serum albumin and cheese 
protein were immediately determined to be allergens. Fur-
ther analysis showed that the allergenicity of cowpea trypsin 
inhibitor may vary depending upon whether or not the sig-
nal peptide was present. In addition, our study of the litera-
ture identified 11 transgenes (-glucuronidase, phytase, ly-
sozyme, ribosomal passivate protein, antithrombin III, tissue 
plasminogen activator, -antitrypsin, lactoferrin, insulin, he-
moglobin, and decay accelerating factor) that were related to 
allergies or clinically adverse events in a series of reports; 
all 11 transgenes had been determined to be non-allergenic 
by EVALLER. The various procedures in the analysis path-
way apparently can complement each other, and could be 
used effectively at the beginning of any project to the trans-
formation of a potentially harmful gene. This would avoid a 
great waste of early substantial investments and help reduce 
public distrust of GMOs. 
The weight-of-evidence approach proposed by the Codex 
Alimentarius Commission guidelines (2003) has been  
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Figure 4  Evaluation of the allergenicity of cell cycle regulatory protein gene (cyclAt, ID #1 transgene of plant source in Table S1) showing the 5 best- 
matching FLAPs.  
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partially accepted. The guidelines require that assessments 
holistically estimate the risk of allergenicity in transgenic 
products based on multiple lines of evidence, including the 
history of exposure and safety of the gene(s) source, protein 
structure, stability to pepsin digestion in vitro, an estimate 
of exposure of the novel protein(s) to the gastrointestinal 
tract where absorption occurs, specific IgE binding studies 
or skin prick testing, and when appropriate, animal models 
and targeted sera screening [38]. However, such approaches 
for predicting protein allergenicity have not been thorough-
ly evaluated or validated [38] nor have any one of them 
been confirmed in humans [39]. Herman et al. [40] showed 
an inconsistency between two criteria widely used for data-
base queries in allergenicity assessment. In their study, al-
lergen-sequence pairs that shared only an 8-amino-acid 
identity and not >35% identity over 80 amino acids were 
unlikely to be cross-reactive allergens. In contrast, sequence 
pairs with >35% identity over 80 amino acids were likely to 
be comparably allergenic. 
EVALLER 2.0 includes 578 types of allergens and 2890 
allergen-representative peptides [1]. This tool reliably as-
sesses the allergenicity of transgene proteins using identities 
over 24 amino acids. On the one hand, sequence similarity 
may provide a preliminary judgment of allergenicity be-
cause sequential determinants play a major role in the aller-
genicity of a protein; however, on the other hand, confor-
mational determinants are another important factor in aller-
gy and these are not accounted for in the analysis of se-
quence similarity. Serological or other immunological tests 
should follow any bioinformatics study, to investigate 
whether the target protein could bind with a specific IgE 
and to obtain a more accurate evaluation for allergenicity of 
the GMOs consumed by humans. This is illustrated in our 
study in which we were able to identify the 11 allergenic 
transgenes not determined by EVALLER based on allergies 
or clinically adverse events reported in the literature. 
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